Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.

Saved in:
Bibliographic Details
Title: Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.
Authors: Goodall RL; MRC Clinical Trials Unit at UCL, University College London, London, UK. Electronic address: r.goodall@ucl.ac.uk., Nunn AJ; MRC Clinical Trials Unit at UCL, University College London, London, UK., Meredith SK; MRC Clinical Trials Unit at UCL, University College London, London, UK., Bayissa A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Bhatnagar AK; Rajan Babu Institute for Pulmonary Medicine & Tuberculosis, Delhi, India., Chiang CY; Department of Internal Medicine, Wan Fang Hospital, Taipei, Taiwan; School of Medicine, Taipei Medical University, Taipei, Taiwan; International Union Against Tuberculosis and Lung Disease, Paris, France., Conradie F; Empilweni TB Hospital, Gqeberha (Port Elizabeth), South Africa., Gopalan N; ICMR-National Institute for Research in Tuberculosis, Chennai, India., Gurumurthy M; Vital Strategies, Singapore., Kirenga B; Makerere University Lung Institute, Mulago Hospital, Kampala, Uganda., Kiria N; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia., Meressa D; St Peter's Tuberculosis Specialized Hospital and Global Health Committee, Addis Ababa, Ethiopia., Moodliar R; THINK: Tuberculosis & HIV Investigative, Doris Goodwin Hospital, Pietermaritzburg, South Africa., Ngubane N; King Dinuzulu Hospital Complex, Durban, South Africa., Rassool M; Clinical HIV Research Unit, Helen Joseph Hospital, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa., Sanders K; MRC Clinical Trials Unit at UCL, University College London, London, UK., Solanki R; B J Medical College, Ahmedabad, India., Squire SB; Liverpool School of Tropical Medicine, Liverpool, UK., Teferi M; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Torrea G; Institute of Tropical Medicine, Antwerp, Belgium., Tsogt B; Mongolian Anti-Tuberculosis Coalition, Ulaanbaatar, Mongolia., Tudor E; Institute of Phthisiopneumology 'Chiril Draganiuc', Chisinau, Moldova., Van Deun A; Institute of Tropical Medicine, Antwerp, Belgium., Rusen ID; Vital Strategies, New York, NY, USA.
Corporate Authors: STREAM study collaborators
Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2024 Dec; Vol. 12 (12), pp. 975-987. Date of Electronic Publication: 2024 Oct 01.
Publication Type: Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-2619
DOI:10.1016/S2213-2600(24)00186-3